cervical carcinoma
Conditions
Interventions
treatment group:Zimberelimab
Sponsors
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Postmenopausal women with sexual history; 2. The pathological diagnosis of biopsy tissue of cervical lesions was cervical squamous cell carcinoma, and the FIGO staging was IB3-IIA2; 3. Have not received any treatment related to cervical cancer before treatment; 4. Before treatment, PETCT or MRI showed tumor volume>5.0 cm; 5. The number of white blood cells and platelets are within the normal range, the total bilirubin, AST, ALT are less than 1.5 times the upper limit of the normal value, and the serum creatinine and serum urea nitrogen are within the normal range; 6. Highly cooperative, willing to participate in the project and signed the informed consent form manually.
Exclusion criteria
Exclusion criteria: 1. Diagnosis that does not conform to this item; 2. Pregnant or lactating women; 3. Patients with active or suspected autoimmune diseases need systematic treatment; 4. People living with HIV; 5. Those who have used corticosteroids 3 months before treatment or need to use large doses of corticosteroids for systemic treatment during treatment; 6. Cardiac insufficiency (NYHA grade III-IV), developmental malformation of liver and kidney or history of surgery, nervous system disorder or lack of autonomic activity; 7. Alcohol or drug abusers; 8. Those who are unable or unwilling to cooperate actively.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pathologic complete remission, PCR;Major pathologic response rates, MPR; | — |
Countries
China
Contacts
Public ContactGuiling LI, Shouhua Yang
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed